CHICAGO -- Treatment with the CDK4/6 inhibitor abemaciclib (Verzenio) offered a dramatic survival uptick in a highly aggressive soft-tissue cancer ...

CHICAGO -- The adjuvant treatment of RET fusion-positive non-small-cell lung cancer (NSCLC) following potentially curative surgery or radiotherapy has a ...

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold. Medscape ...

Peptides have moved from bodybuilding forums into the cultural mainstream. Telehealth clinics advertise them for weight loss and recovery, often ...

CHICAGO -- Men with metastatic castration-sensitive prostate cancer (mCSPC) and DNA repair alterations had significantly longer progression-free survival (PFS) with ...

Experts at the Primary Care Show identified the key barriers to lipid management — and what clinicians can do about ...

In the first phase 3 trial of a RET inhibitor as adjuvant therapy, selpercatinib markedly improved event-free survival vs placebo ...

CHICAGO -- RASolute 302 trial results were hailed as a game-changing breakthrough in the treatment of pancreatic cancer. The phase ...

Rochelle Lewis is among more than 170 million woman globally to be diagnosed with PCOS. Source link : https://www.bbc.com/news/articles/cd9p50j3ljko?at_medium=RSS&at_campaign=rss Author ...

CHICAGO -- Adding an investigational TROP2-targeted antibody-drug conjugate (ADC) to first-line immunotherapy for PD-L1-positive non-small cell lung cancer (NSCLC) reduced ...

When an oncologist learns one patient’s story, everything shifts, including his approach to consultations. Medscape Medical News Source link : ...

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine ...

Patients in full remission from endometrial cancer who underwent fertility-preserving treatment before cancer treatment had less IVF success than matched ...

I have spent 20 years working in out-of-network healthcare reimbursement. After reading the New York Times article "A $440,000 Breast ...

CHICAGO -- Combining two targeted therapies with standard-of-care chemotherapy extended progression-free survival (PFS) in patients with newly diagnosed B-cell lymphomas, ...

President Donald Trump on Friday gave his endorsement to a January study by HHS that calls for cutting the number ...

Editor's Note: This story includes discussion of suicide. If you or someone you know needs help, the national suicide and ...

The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast ...

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, ...

The GammaTile may improve outcomes over standard stereotactic RT after resection of large brain metastases, but a striking overall survival ...